Related Experiment Videos

Response of different mammary epithelial cell lines to a mammary derived growth inhibitor (MDGI)

W Lehmann1, R Widmaier, P Langen

  • 1Department of Cell Kinetics, Academy of Sciences of the GDR, Berlin-Buch.

Biomedica Biochimica Acta
|January 1, 1989
PubMed

Insights

Mammary-derived growth inhibitor (MDGI) inhibits proliferation in human and mouse malignant mammary epithelial cells and normal human mammary epithelial cells. MDGI

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • MDGI is a 14.5-KDa protein purified from bovine mammary glands.
  • MDGI's inhibitory activity was previously characterized in mouse Ehrlich ascites mammary tumor (EAT) cells.

Purpose of the Study:

  • To investigate MDGI's inhibitory activity on human and mouse malignant mammary epithelial cell lines.
  • To assess MDGI's effect on normal human mammary epithelial cells (HMEC).

Main Methods:

  • Cells were rendered quiescent via serum/growth factor deprivation.
  • [3H]TdR pulse labeling measured proliferation restimulation.
  • MDGI's activity was tested on four malignant and normal mammary epithelial cell lines.

Main Results:

  • MDGI inhibited MaTu, T47D, and mMaCa 20177 cell lines.
  • MCF7 cell line showed slight stimulation; no residual DNA synthesis inhibition was observed.
  • Normal HMEC cells were inhibited, with higher sensitivity in later passages (10-14).
  • Growth factors (insulin, EGF, FCS) did not abolish MDGI's inhibitory effect on HMEC.

Conclusions:

  • MDGI exhibits inhibitory activity beyond EAT cells.
  • MDGI affects both malignant and normal mammary epithelial cells.
  • MDGI's activity on normal cells is potent and not fully antagonized by common growth factors.

Related Concept Videos